Regenera set to begin Singapore trials

By Melissa Trudinger
Tuesday, 03 August, 2004

Regenera (ASX: RGA) has received ethics committee approval to begin Phase III human clinical trials for its synthetic steroid drug Visagen at the Singapore Eye Research Institute.

The initial trial will test the treatment on cystoid macular oedema, and the company plans to expand the study with trials evaluating the therapy in age related macular degeneration, uveitis, diabetic macular oedema and as a co-treatment with photodynamic therapy.

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...

Content from other channels on our network

Driving change: how electric vehicles are fuelling Australia's sustainable businesses

CSIRO gathers innovators to tackle plastic waste

Trinasolar launches agrivoltaics project in NZ

South East Water takes home R&D Excellence Award

Mars Petcare unveils renewable energy plan

Medline introduces Namic Ready Set Kits

Solventum innovations enabling better, smarter, safer healthcare

Lumia Care expands national network with SA acquisition

Funding to support cervical cancer screening and treatment in the Pacific

Packaged foods: strict salt targets could prevent 40K cardiovascular events

Scooping Up Success: Sajani Cups and Cones Freezes Out Stock Issues with Fishbowl

Managing Food Safety Risk Efficiently with Data Automation

Introducing Tool-Free Mounting and Reduced Service Times with Bürkert's Direct Acting Service Valves

Hygiene-first cables and connectors for the food and beverage industry

Futurecasting Food Science with data